Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B Virus
Trial details
- Registry ID
- NCT02452528
- Phase
- Phase 2
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| Study of ARC-520 in Participants With Hepatitis B Virus e Antigen (HBeAg) Positive Chronic Hepatitis B VirusNCT02452528 | Arrowhead Pharmaceuticals | Phase 2 | Terminated | 2016-12Actual |
| No regulatory events match this view.This does not mean no FDA events have occurred. |